Genitourinary Cancer

1:08
Research highlights in nmCRPC: PROSPER and SPARTAN studies
Andrew Armstrong
1:45
Targeting plasticity pathways for novel therapy in prostate cancer
Andrew Armstrong
3:28
Understanding bone metastases formation in patients with prostate cancer
Andrew Armstrong
2:16
The agents at the forefront of kidney cancer treatment
Michael Atkins
3:30
Promising results for axitinib and pembrolizumab in advanced renal cell cancer
Michael Atkins
1:31
Combining immunotherapy with VEGF inhibitors to treat kidney cancer
Michael Atkins
1:37
The impact of PSA in prostate cancer and its limitations
Francesco Montorsi
3:32
Debating the future of prostate cancer management
Francesco Montorsi
1:08
Systemic treatments for non-muscle invasive bladder cancer
Peter Black
1:52
Can atezolizumab succeed where BCG fails in bladder cancer?
Peter Black
2:48
Using biomarkers to identify bladder cancer patients for neoadjuvant therapy
Peter Black
2:25
Molecular aging and p16INK4a in testicular cancer survivors
Maria Teresa Bourlon
3:04
Success of novel immunotherapies for renal cell carcinoma
Jeanny Aragon-Ching
2:00
Future therapy options for muscle-invasive bladder cancer
Jeanny Aragon-Ching
2:07
Differences in survival rates among non-urothelial bladder cancers
Jeanny Aragon-Ching
3:23
FALCON: radiopharmaceuticals for the management of recurrent prostate cancer
Eugene Teoh
VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals